| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
61,398,000 |
| Market
Cap: |
283.66(M) |
| Last
Volume: |
821,939 |
Avg
Vol: |
693,736 |
| 52
Week Range: |
$3.38 - $6.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 803 |
| Guru Rank Value : 1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vanda Pharmaceuticals is a biopharmaceutical company. Co.'s commercial portfolio is comprised of two products, HETLIOZ® for the treatment of Non-24 Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt® for the treatment of schizophrenia. In addition, Co. has a number of drugs in development, including: Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; and VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
121,098 |
121,098 |
148,134 |
388,157 |
| Total Sell Value |
$513,345 |
$513,345 |
$684,141 |
$2,735,436 |
| Total People Sold |
5 |
5 |
6 |
8 |
| Total Sell Transactions |
10 |
10 |
14 |
33 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Moran Kevin Patrick |
SVP, CFO & Treasurer |
• – – |
2022-07-28 |
4 |
S |
$10.97 |
$24,562 |
D/D |
(2,239) |
117,452 |
|
1% |
|
| Ward Anne Sempowski |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
12,006 |
22,006 |
|
- |
|
| Mitchell Stephen Ray |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
12,006 |
18,521 |
|
- |
|
| Chrousos Phaedra |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
12,006 |
24,931 |
|
- |
|
| Dugan Richard W |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
12,006 |
80,393 |
|
- |
|
| Watkins Thomas |
Director |
– • – |
2022-06-02 |
4 |
S |
$9.90 |
$63,779 |
D/D |
(6,441) |
63,064 |
|
2% |
|
| Watkins Thomas |
Director |
– • – |
2022-06-02 |
4 |
OE |
$4.15 |
$62,250 |
D/D |
15,000 |
69,505 |
|
- |
|
| Dugan Richard W |
Director |
– • – |
2022-05-31 |
4 |
S |
$9.85 |
$64,052 |
D/D |
(6,500) |
68,387 |
|
0% |
|
| Dugan Richard W |
Director |
– • – |
2022-05-31 |
4 |
OE |
$4.15 |
$62,250 |
D/D |
15,000 |
74,887 |
|
- |
|
| Wijkstrom Joakim |
SVP, Chief Marketing Officer |
• – – |
2022-03-02 |
4 |
S |
$11.19 |
$78,060 |
D/D |
(6,974) |
100,278 |
|
-1% |
|
| Polymeropoulos Mihael Hristos |
President and CEOChairman of t |
• • – |
2022-03-02 |
4 |
S |
$11.15 |
$329,945 |
D/D |
(29,588) |
1,352,766 |
|
-1% |
|
| Birznieks Gunther |
SVP, Business Development |
• – – |
2022-03-02 |
4 |
S |
$11.27 |
$129,792 |
D/D |
(11,517) |
188,807 |
|
-1% |
|
| Moran Kevin Patrick |
SVP, CFO & Treasurer |
• – – |
2022-03-02 |
4 |
S |
$11.28 |
$99,650 |
D/D |
(8,832) |
119,691 |
|
-1% |
|
| Williams Timothy |
SVP & General Counsel |
• – – |
2022-03-02 |
4 |
S |
$11.09 |
$133,779 |
D/D |
(12,060) |
103,851 |
|
-1% |
|
| Polymeropoulos Mihael Hristos |
President and CEOChairman of t |
• • – |
2022-03-01 |
4 |
S |
$11.19 |
$84,015 |
D/D |
(7,508) |
1,382,354 |
|
1% |
|
| Birznieks Gunther |
SVP, Business Development |
• – – |
2022-03-01 |
4 |
S |
$11.19 |
$45,700 |
D/D |
(4,084) |
200,324 |
|
1% |
|
| Moran Kevin Patrick |
SVP, CFO & Treasurer |
• – – |
2022-03-01 |
4 |
S |
$11.19 |
$38,863 |
D/D |
(3,473) |
128,523 |
|
1% |
|
| Wijkstrom Joakim |
SVP, Chief Marketing Officer |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
32,700 |
107,252 |
|
- |
|
| Polymeropoulos Mihael Hristos |
President and CEOChairman of t |
• • – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
115,000 |
1,389,862 |
|
- |
|
| Birznieks Gunther |
SVP, Business Development |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
32,700 |
204,408 |
|
- |
|
| Moran Kevin Patrick |
SVP, CFO & Treasurer |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
32,700 |
131,996 |
|
- |
|
| Williams Timothy |
SVP & General Counsel |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
32,700 |
115,911 |
|
- |
|
| Jones Aranthan Ii |
Chief Corp. Affairs Officer |
• – – |
2021-09-15 |
4 |
S |
$16.49 |
$277,394 |
D/D |
(16,824) |
81,980 |
|
10% |
|
| Jones Aranthan Ii |
Chief Corp. Affairs Officer |
• – – |
2021-09-15 |
4 |
OE |
$11.32 |
$141,250 |
D/D |
12,119 |
98,804 |
|
- |
|
| Mitchell Stephen Ray |
Director |
– • – |
2021-09-09 |
4 |
S |
$16.74 |
$319,976 |
D/D |
(19,109) |
9,215 |
|
16% |
|
549 Records found
|
|
Page 3 of 22 |
|
|
0.14 (3.12%) 
